spacer
home > ebr > autumn 2018 > effective electroceuticals
PUBLICATIONS
European Biopharmaceutical Review

Effective Electroceuticals

Pain is a normal physiologic signal by which the brain communicates to an individual that tissues in the body are in danger or have already been damaged. Typically, when the tissue damaging agent is removed or the tissue heals, the pain subsides. However, sometimes, even long after the tissues have healed, the brain continues to sense pain – this is classified as chronic pain. More specifically, the International Association for the Study of Pain (IASP) defines pain as chronic if it lasts for more than three to six months (1). Chronic pain can manifest as musculoskeletal, neuropathic, or idiopathic, but, most importantly, it can significantly reduce quality of life due to both physical and emotional impacts on the individual. Chronic pain is remarkably prevalent, affecting up to 30% of the global population, reflecting a global therapeutic market that is expected to exceed US $83 billion by 2024, or approximately onethird the size of total current biopharmaceutical markets (2-3).

Currently, three main classes of traditional pharmacologic interventions (OTC and prescription) are used to manage pain: 1) opioids/opioid-like agents/opioid-analgesic combinations; 2) NSAID’s/analgesics; and 3) adjuvant therapies such as antidepressants, anti-convulsants, anti-rheumatics/immunologics, muscle relaxants, topical products, and corticosteroids. Biopharmaceutical approaches to pain management have not, to date, been extensively pursued. In part, this may be because biopharmacologic approaches tend to be more focussed on personalised therapies, and pain is often considered a generic healthcare challenge (4). However, recent developments in pain management suggest an opportunity for the development of targeted therapies, a strategy that may fit well with the biopharma industry’s long-term goals (5).

Central Sensitisation

The neurophysiologic understanding of pain management is founded on the work of Melzack and Wall who introduced the Gate Control Theory in the mid-1960s (6). The commonly observed phenomenon of reducing pain sensation by rubbing injured tissue was explained in this theory as the ability of fast, sensory nerve fibers serving to block the activity of the slow, noxious nerve fibres. This theory quickly led to the development of transcutaneous electrical nerve stimulation (TENS) technology as a means to block pain and therefore provide a non-pharma approach to pain management. While it is not practical to ‘rub’ injured tissue continuously, an electrical stimulator using electrode pads on the skin to permit electrical current injection can readily be designed to operate for hours, thereby providing sustained pain relief. However, sustained electrical stimuli in and of themselves can be irritating, and, furthermore, high electrical current densities injected through the electrode pads can damage skin, so usage is typically limited to a few hours per day.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Sree Koneru obtained his doctoral degree in biomedical engineering from the State University of New York at Binghamton, US. His research expertise is in investigating physiological responses of pulsed radiofrequency EMF for the development of advanced electroceutical devices. Sree leads new product development at BioElectronics Corporation.

Dr Kenneth McLeod obtained his doctoral degree in electrical engineering from the Massachusetts Institute of Technology, US. His research is focussed on musculoskeletal adaptation, with a particular focus on electromagnetic interactions with living tissue. Kenneth serves as Director of the Clinical Science and Engineering Research Laboratory at the State University of New York in Binghamton, US.
spacer
Dr Sree Koneru
spacer
spacer
spacer
Dr Kenneth McLeod
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Introducing Signant Health [Formerly CRF Bracket] and the Industry’s Most Comprehensive Patient-Centric Suite for Clinical Research

Philadelphia and London – June 10, 2019: CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, today launched as Signant Health (signanthealth.com). Uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite, Signant makes it easier to participate in – and sites and study teams to run – clinical trials. This intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable sponsors and CROs to extend the reach of drug development, expand patient opportunities and improve data quality.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement